Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #99 on PTC Therapeutics Inc (PTCT)
legalizeMJ
09/19/16 7:24 PM
#109 RE: girlfriend #99
Additionally, William Blair analysts noted that Sarepta should "move into a hyper-growth phase" of profit generation as there is currently no competition in the DMD drug market. William Blair upgraded the stock to "outperform" from "market perform" and set its price target at $88.